Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.pSivida has signed a technology evaluation agreement with Neuron Systems for its bioerodible Durasert drug delivery technology in ophthalmology.
Subscribe to our email newsletter
As per the agreement, the use of pSivida’s technology as a delivery system for a treatment for dry age related macular degeneration (Dry AMD) will be evaluated.
pSivida president and CEO Paul Ashton said this is the second tech evaluation agreement for bioerodible Durasert technology since the company regained the rights to its intellectual property from Pfizer.
Neuron CEO Todd Brady said the combination of Durasert and its proprietary compounds may provide an exciting new approach to treating the devastating disease.